Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Diabetes mellitus type 1 Stories

2014-02-27 12:26:43

DUBLIN, February 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/9cwh4j/diabetes_app) has announced the addition of the "Diabetes App Market Report 2014" [http://www.researchandmarkets.com/research/9cwh4j/diabetes_app ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Diabetes App Market Report 2014 is a comprehensive analysis about the performance of diabetes apps, key...

2014-02-27 08:30:14

VitalPak designed to discretely organize essential medical supplies for secure, easy transport FRANKLIN, Wis., Feb. 27, 2014 /PRNewswire/ -- Two inventors from Franklin, WI, Kyle Houlihan, a 9-year-old diabetic, and his father, Tom, are raising funds to bring the VitalPak Medical Backpack to market. The VitalPak is designed for people with medical conditions who need essential supplies with them at all times. (Photo: http://photos.prnewswire.com/prnh/20140227/PH72883-a ) (Photo:...

2014-02-25 14:23:10

The automatic “threshold suspend” (TS) feature of an insulin pump helps prevent life-threatening hypoglycemic events when the device's sensor detects blood glucose concentrations below the preset threshold. However, in individuals with type 1 diabetes who have had previous episodes of hypoglycemia the TS feature may be less effective at preventing subsequent events, according to important new results from the ASPIRE study published in Diabetes Technology & Therapeutics (DTT), a...

2014-02-18 23:27:40

DNS Made Easy, the creators of Constellix, sponsors the 9th Annual Dodging Diabetes charity dodge ball tournament. Reston, VA (PRWEB) February 18, 2014 It’s time to dip, dive, duck and dodge. For team Constellix, joining the 9th Annual Dodging Diabetes charity dodge ball tournament March 9 is about building team spirit and workplace camaraderie. However, the ultimate goal is to help support the Juvenile Diabetes Research Foundation and the Joslin Diabetes Center. The Dodging Diabetes...

2014-02-12 08:30:06

More than half a million dollars donated to help children with diabetes attend camp since 2008 INDIANAPOLIS and ALEXANDRIA, Va., Feb. 12, 2014 /PRNewswire/ -- News Highlights: -- #Lilly #Diabetes supports @AmDiabetesAssn #camps by donating $91,000 to send 91 children with diabetes to camp in 2014 -- #Lilly #Diabetes donates $91,000 to the @AmDiabetesAssn 2014 #camp program -- #Lilly #Diabetes supports scholarship program for children with #T1 #diabetes;...

2014-02-12 08:28:24

Clinical program focused on reversing type 1 diabetes symptoms in patients diagnosed within six months of trial initiation EDGEWATER, N.J. and SAN DIEGO, Feb. 12, 2014 /PRNewswire/ -- DiaVacs, Inc., a clinical stage biotechnology company focused on developing cell-based therapy for treatment of type 1 diabetes, and Profil(® )Institute for Clinical Research, Inc., an early phase clinical research organization focused on diabetes and obesity, announced today a strategic collaboration...

2014-02-11 12:27:38

The Biggest Loser RunWalk and The Biggest Loser Resorts Will Sponsor 5K Race at Annual Event Which Raises Funds for Diabetes Research Institute MIAMI, Feb. 11, 2014 /PRNewswire-USNewswire/ -- The Diabetes Research Institute Foundation has once again teamed up with Walgreens, the nation's largest drugstore chain, for the DRI Walk for Diabetes & Family Fun Day. This marquee event along with The Biggest Loser RunWalk 5K will be held the morning of Saturday, March 8, 2014 at Sun Life...

2014-02-11 08:32:23

LA CHAUX-DE-FONDS, Switzerland, February 11, 2014 /PRNewswire/ -- Kareus Therapeutics SA ("Kareus") announced today that US FDA has approved its Investigational New Drug (IND) KU-5039 to initiate Phase I clinical trial. KU 5039 is being developed for the treatment of insulin resistance and diabetes. KU-5039 is an orally active, New Chemical Entity (NCE), discovered and developed by Kareus. KU-5039 is a potent and selective activator of AMP-kinase (AMPK), a key...

2014-02-10 12:25:17

JERUSALEM, Feb. 10, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted a protocol to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes. The protocol was submitted under Oramed's existing IND for ORMD-0801 to include both...

2014-02-07 13:00:08

Insulin use to treat type 2 diabetes trebles over 20 years "Understanding the pattern of insulin use is limited by a lack of data characterizing the prevalence of insulin use in the UK," according to Craig Currie, Professor of Applied Pharmacoepidemiology at Cardiff University's School of Medicine, who led the study alongside colleagues from the University of Bristol. "Given the limitations, our study sought to calculate – for the first time – the best possible estimate of the rates...


Latest Diabetes mellitus type 1 Reference Libraries

Diabetes (journal)
2012-05-12 21:44:48

Diabetes is a peer-reviewed medical journal published since 1952 by the American Diabetes Association. Diabetes is a separate journal from the journal Diabetes Care, which is also published by the ADA. Diabetes covers research about the physiology and pathophysiology of diabetes mellitus, including any aspect of laboratory, animal or human research. Emphasis is on investigative reports focusing on areas such as the pathogenesis of diabetes and its complications, normal and pathologic...

More Articles (1 articles) »